Background: High-pathogenicity avian influenza viruses continue to circulate in poultry and wild birds and occasionally infect humans, sometimes with fatal outcomes. Development of vaccines is a priority to prepare for potential pandemics but is complicated by antigenic variation of the surface glycoprotein hemagglutinin. We report the immunological profile induced by human immunization with modified vaccinia virus Ankara (MVA) expressing the hemagglutinin gene of influenza A(H5N1) virus A/Vietnam/1194/04 (rMVA-H5). Methods: In a double-blinded phase 1/2a clinical trial, 79 individuals received 1 or 2 injections of rMVA-H5 or vector control. Twenty-seven study subjects received a booster immunization after 1 year. The breadth, magnitude, and properties of vaccine-induced antibody and T-cell responses were characterized. Results: rMVA-H5 induced broadly reactive antibody responses, demonstrated by protein microarray, hemagglutination inhibition, virus neutralization, and antibody-dependent cellular cytotoxicity assays. Antibodies cross-reacted with antigenically distinct H5 viruses, including the recently emerged subtypes H5N6 and H5N8 and the currently circulating subtype H5N1. In addition, the induction of T cells specific for H5 viruses of 2 different clades was demonstrated. Conclusions: rMVA-H5 induced immune responses that cross-reacted with H5 viruses of various clades. These findings validate rMVA-H5 as vaccine candidate against antigenically distinct H5 viruses. Clinical Trials Registration: NTR3401.
RCT Entities:
Background: High-pathogenicity avian influenza viruses continue to circulate in poultry and wild birds and occasionally infect humans, sometimes with fatal outcomes. Development of vaccines is a priority to prepare for potential pandemics but is complicated by antigenic variation of the surface glycoprotein hemagglutinin. We report the immunological profile induced by human immunization with modified vaccinia virus Ankara (MVA) expressing the hemagglutinin gene of influenza A(H5N1) virus A/Vietnam/1194/04 (rMVA-H5). Methods: In a double-blinded phase 1/2a clinical trial, 79 individuals received 1 or 2 injections of rMVA-H5 or vector control. Twenty-seven study subjects received a booster immunization after 1 year. The breadth, magnitude, and properties of vaccine-induced antibody and T-cell responses were characterized. Results:rMVA-H5 induced broadly reactive antibody responses, demonstrated by protein microarray, hemagglutination inhibition, virus neutralization, and antibody-dependent cellular cytotoxicity assays. Antibodies cross-reacted with antigenically distinct H5 viruses, including the recently emerged subtypes H5N6 and H5N8 and the currently circulating subtype H5N1. In addition, the induction of T cells specific for H5 viruses of 2 different clades was demonstrated. Conclusions: rMVA-H5 induced immune responses that cross-reacted with H5 viruses of various clades. These findings validate rMVA-H5 as vaccine candidate against antigenically distinct H5 viruses. Clinical Trials Registration: NTR3401.
Authors: Catharine I Paules; Hilary D Marston; Robert W Eisinger; David Baltimore; Anthony S Fauci Journal: Immunity Date: 2017-10-17 Impact factor: 31.745
Authors: Paul E Leon; Wenqian He; Caitlin E Mullarkey; Mark J Bailey; Matthew S Miller; Florian Krammer; Peter Palese; Gene S Tan Journal: Proc Natl Acad Sci U S A Date: 2016-09-19 Impact factor: 11.205
Authors: Martin Linster; Sander van Boheemen; Miranda de Graaf; Eefje J A Schrauwen; Pascal Lexmond; Benjamin Mänz; Theo M Bestebroer; Jan Baumann; Debby van Riel; Guus F Rimmelzwaan; Albert D M E Osterhaus; Mikhail Matrosovich; Ron A M Fouchier; Sander Herfst Journal: Cell Date: 2014-04-10 Impact factor: 41.582
Authors: Sinthujan Jegaskanda; Karen L Laurie; Thakshila H Amarasena; Wendy R Winnall; Marit Kramski; Robert De Rose; Ian G Barr; Andrew G Brooks; Patrick C Reading; Stephen J Kent Journal: J Infect Dis Date: 2013-06-28 Impact factor: 5.226
Authors: Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Travis S Hottes; James A Dickinson; Natasha Crowcroft; Trijntje L Kwindt; Patrick Tang; Hugues Charest; Kevin Fonseca; Jonathan B Gubbay; Nathalie Bastien; Yan Li; Martin Petric Journal: BMJ Date: 2011-02-03
Authors: Arwen F Altenburg; Joost H C M Kreijtz; Rory D de Vries; Fei Song; Robert Fux; Guus F Rimmelzwaan; Gerd Sutter; Asisa Volz Journal: Viruses Date: 2014-07-17 Impact factor: 5.048
Authors: Leonie M Weskamm; Anahita Fathi; Matthijs P Raadsen; Anna Z Mykytyn; Till Koch; Michael Spohn; Monika Friedrich; Bart L Haagmans; Stephan Becker; Gerd Sutter; Christine Dahlke; Marylyn M Addo Journal: Cell Rep Med Date: 2022-07-19
Authors: Kelsey Florek; James Mutschler; Huong Q McLean; Jennifer P King; Brendan Flannery; Edward A Belongia; Thomas C Friedrich Journal: Vaccine Date: 2019-11-18 Impact factor: 3.641
Authors: Courtney E Meilleur; Arash Memarnejadian; Adil N Shivji; Jenna M Benoit; Stephen W Tuffs; Tina S Mele; Bhagirath Singh; Jimmy D Dikeakos; David J Topham; Hong-Hua Mu; Jack R Bennink; John K McCormick; S M Mansour Haeryfar Journal: PLoS Pathog Date: 2020-05-20 Impact factor: 6.823
Authors: Rie Nakajima; Medalyn Supnet; Algis Jasinskas; Aarti Jain; Omid Taghavian; Joshua Obiero; Donald K Milton; Wilbur H Chen; Michael Grantham; Richard Webby; Florian Krammer; Darrick Carter; Philip L Felgner; D Huw Davies Journal: mSphere Date: 2018-12-12 Impact factor: 4.389
Authors: Chih-Jen Wei; Michelle C Crank; John Shiver; Barney S Graham; John R Mascola; Gary J Nabel Journal: Nat Rev Drug Discov Date: 2020-02-14 Impact factor: 84.694